Kyverna Therapeutics, Inc. (KYTX)
5.15
-0.01
(-0.19%)
USD |
NASDAQ |
Nov 04, 16:00
5.12
-0.03
(-0.58%)
After-Hours: 19:39
Kyverna Therapeutics Debt to Equity Ratio : 0.1993 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1993 |
| March 31, 2026 | 0.1726 |
| December 31, 2025 | 0.125 |
| September 30, 2025 | 0.0331 |
| June 30, 2025 | 0.0321 |
| March 31, 2025 | 0.031 |
| December 31, 2024 | 0.0309 |
| September 30, 2024 | 0.0302 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.03 |
| March 31, 2024 | 0.03 |
| December 31, 2023 | 0.1846 |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 0.2263 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 219.82M |
| Total Liabilities (Quarterly) | 54.27M |
| Shareholders Equity (Quarterly) | 165.55M |
| Current Ratio | 9.058 |
| Net Debt Paydown Yield | -0.95% |